Overview

* Concentra Q2 2025 revenue rises 15.2%, beating analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 2025 beats consensus, reflecting operational efficiencies

* Company raises FY 2025 guidance, indicating confidence in future performance

Outlook

* Concentra raises FY 2025 revenue guidance to $2.13 bln-$2.16 bln

* Company expects FY 2025 Adjusted EBITDA of $420 mln-$430 mln

* Concentra targets net leverage ratio of 3.5x by year-end

* Company maintains FY 2025 capital expenditure forecast at $80 mln-$90 mln

Result Drivers

* PATIENT VISITS - Increase in patient visits by 9.5% contributed to revenue growth

* ACQUISITIONS - Integration of Nova Medical Centers and Pivot Onsite Innovations drove operational efficiencies

* REVENUE PER VISIT - Revenue per visit rose 4.4%, supporting top-line growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $550.78 $537.40

Revenue mln mln (8

Analysts

)

Q2 EPS $0.35

Q2 Net $46.19

Income mln

Q2 Beat $115 mln $112.70

Adjusted mln (6

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Concentra Group Holdings Parent Inc ( CON ) is $28.00, about 28.8% above its August 6 closing price of $19.94

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)